Drug Database
Back to search

Netherlands· NL-4ebc50714d32

Orap 1 mg, tabletten

A pimozide product containing pimozide, registered in Netherlands by EU-Pharma B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC N05AG02

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOrap 1 mg, tablettenATCN05AG02REGISTER NO.NL-4ebc50714d32PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about pimozideAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Pimozide is registered in 11 of 19 countries.

Countries holding a registration under ATC N05AG02 (pimozide), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose
Search pimozide products by name

Pimozide · ATC N05AG02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Italyprice
  • Netherlands
  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of pimozide costs, country by country.

Normalised to the WHO defined daily dose (4 mg), the median price runs from $0.18 in France to $0.31 in Italy — a ×1.7 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Pimozide · price per daily dose (4 mg)

USD · FX 28 Sept 2026

  • IT Italy$0.31
  • FR France$0.18
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
PIMOZIDE
Manufacturer
EU-Pharma B.V.
Country
Netherlands (NL)
ATC code
N05AG02
ATC class
Pimozide
Defined daily dose
4 mg, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    26480//06149

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

317 interactions on record for pimozide.

Graded by severity as the source publishes them — 174 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check pimozide against other medicinesHow interaction checks work

Pimozide · interactions on record

317 records

  • 174 severe
  • 140 moderate
  • 3 minor

Most severe, free to view

  • CimetidineA02BA01severe
  • MetoclopramideA03FA01severe
  • CisaprideA03FA02severe
  • OndansetronA04AA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Pimozide in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All pimozide products

Authorised across Europe · EMA

The same active substance is authorised in 11 EEA countries. Names it is sold under:

  • Belgium · Orap, Orap Forte
  • Germany · Orap, Orap Forte
  • Denmark · Orap
  • Spain · Orap, Orap Fuerte
  • France · Orap
  • United Kingdom (Northern Ireland) · Orap
  • Greece · Pirium
  • Italy · Orap
  • Luxembourg · Orap, Orap Forte
  • Malta · Orap
  • Portugal · Orap Forte

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/13e253d1-d4b3-4f8c-b091-83a58bac3c07
GET /v1/drugs/13e253d1-d4b3-4f8c-b091-83a58bac3c07?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h06149_smpc.pdf",
  "strength": null,
  "atc_label": "Pimozide",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg26480",
  "excipients": [
    "CALCIUMWATERSTOFFOSFAAT 2-WATER (E 341)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "IJZEROXIDE GEEL (E 172)",
    "KATOENZAADOLIE, GEHYDROGENEERD",
    "MAÏSZETMEEL",
    "POVIDON K 30 (E 1201)",
    "TALK (E 553b)",
    "ZONNEGEEL FCF ALUMINIUMLAK (E 110)"
  ],
  "substances": [
    "PIMOZIDE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h26480.pdf",
  "authorised_at": "2001/05/01",
  "procedure_number": null,
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "26480//06149",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about pimozide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console